Camber Capital Management’s Medicines Co MDCO Stock Holding History

Camber Capital Management’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,700,000	Closed	-$62M	–	39
2019 Q2	$62M	Sell	1,700,000 -771,523	-31%	-$25.2M	2.89%	14
2019 Q1	$69.1M	Buy	2,471,523 +471,523	+24%	+$11.1M	3.44%	12
2018 Q4	$38.3M	Hold	2,000,000	–	–	1.82%	23
2018 Q3	$59.8M	Hold	2,000,000	–	–	2.56%	16
2018 Q2	$73.4M	Hold	2,000,000	–	–	2.82%	15
2018 Q1	$65.9M	Buy	2,000,000 +400,000	+25%	+$12.5M	3.23%	12
2017 Q4	$43.7M	Buy	+1,600,000	New	+$49.3M	2.14%	17
2016 Q4	–	Sell	-2,000,000	Closed	-$75.5M	–	44
2016 Q3	$75.5M	Hold	2,000,000	–	–	3.32%	10
2016 Q2	$67.3M	Sell	2,000,000 -500,000	-20%	-$17.6M	3.25%	7
2016 Q1	$79.4M	Buy	2,500,000 +300,000	+14%	+$9.8M	4.65%	3
2015 Q4	$82.1M	Sell	2,200,000 -300,000	-12%	-$11.3M	5.31%	4
2015 Q3	$94.9M	Hold	2,500,000	–	–	8.13%	2
2015 Q2	$71.5M	Hold	2,500,000	–	–	4.87%	6
2015 Q1	$70M	Buy	2,500,000 +1,180,000	+89%	+$33.1M	5%	4
2014 Q4	$36.5M	Buy	+1,320,000	New	+$32.7M	2.43%	18

Other funds holding MDCO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Camber Capital Management's MDCO Position: Q3 2019 in Review

Camber Capital Management sold out of Medicines Co (MDCO) in Q3 2019, closing a stake of 1,700,000 shares — an estimated $62M sold.

Camber Capital Management first reported a position in MDCO in Q4 2014 and held it in 15 quarters. The position peaked at $94.9M in Q3 2015. 250 funds tracked by Wall St. Rank hold MDCO as of Q3 2019.

Camber Capital Management reported no remaining Medicines Co position as of Q3 2019 after selling out during the quarter.
Camber Capital Management sold 1,700,000 Medicines Co shares in Q3 2019, an estimated $62M.
Camber Capital Management first reported a position in Medicines Co in Q4 2014 and held it in 15 quarters.
Camber Capital Management's Medicines Co position peaked at $94.9M in Q3 2015.
250 funds tracked by Wall St. Rank held Medicines Co as of Q3 2019.

Based on Camber Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.